The Arizona Biomedical Research Centre announced today that it is now accepting Letters of Intent (LOI) for a new cohort of research grants. The LOI is Phase One of a two-phase process. LOI will be accepted through June 28, 2023. Once the letters are reviewed and scored, select applicants will be invited to submit a full application.Continue reading
Category Archives: AZBio News
Five UArizona Health Sciences researchers selected for Career Development Awards
The University of Arizona Health Sciences Career Development Awards program supports the development of new research by promising young investigators. Five junior faculty members beginning independent research projects are receiving funding through the University of Arizona Health Sciences Career Development Award program.Continue reading
Serva Energy Discovers ‘Highly Promising’ New Way to Produce Cancer-killing Ac-225 Isotope
Tempe, AZ — Serva Energy, a nuclear innovation company, has developed a new production method to ramp up the supply of Actinium-225, a cancer-killing isotope in ultra-high demand by oncology researchers and pharmaceutical companies developing Targeted Alpha Therapies (TAT)—a promising step forward in the fight against cancer.Continue reading
Arizona Board of Regents announces university-led statewide effort to address critical health care workforce shortages
Today, the Arizona Board of Regents announced a comprehensive, university-led statewide effort to address critical workforce shortages among physicians, nurses and other health care professionals. Currently, it is estimated nearly 3 million Arizonans have limited access to primary care, and more than one in three Arizona hospitals face a critical staffing shortage.Continue reading
Patients will lose access to 40% of future medicines because of the IRA, new research finds.
New research released by Vital Transformation (VT) shows that the Inflation Reduction Act (IRA) will stifle the ability of companies to continue research and development across a broad range of therapeutic areas. The effects of the IRA will have a far more serious impact on the development of new medicines than has been reported, according to the research.Continue reading
CEI Offers Course on Creating Your Quality Management System (QMS)
Get an overview of quality systems and understand the what and why founders need to know.Continue reading
GT Medical Technologies Marks a Clinical Milestone: 200th Patient Enrolled in the Multicenter Observational Registry of GammaTile® Therapy
Registry Study of GammaTile Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain NeoplasmsContinue reading
KOL Conversation: The Impact of the IRA on Oncology Patient Care
Impact of the IRA on Oncology Patient Care features an interview with Dr. Barbara L. McAneny, MD, FASCO, MACP Former President for the American Medical Association and the New Mexico Medical Society (NMMS); and currently CEO, New Mexico Cancer Center.
With Dr. Steve Potts CEO, Anticipate Bioscience.
Impact of the IRA on Oncology Patient Care was recorded on the 26th of May 2023Continue reading
Anuncia Medical Inc. Announces Published Data with Promising Clinical Outcomes Using the ReFlow™ Ventricular System In-Line with Hydrocephalus Shunts
SCOTTSDALE, Ariz., May 23, 2023 /PRNewswire/ — Anuncia Medical Inc. (“Anuncia” or the “Company”), a company specializing in advancing innovations for implantable and external cerebrospinal fluid (CSF) management systems and neurocritical care, is pleased to announce that an article highlighting its FDA cleared and CE Marked ReFlow™ Ventricular System “Gen 1” with Hydrocephalus shunts in patients suffering from chronic shunt occlusions, has been published in Pediatric Neurosurgery. Two years prior to being implanted with the ReFlow™ System, 7 of the 9 patients represented in the publication experienced a combined total of 14 proximal shunt failures that required revision. In the 2-4 years following ReFlow™ implantation and use to maintain flow, only 1 proximal shunt failure occurred amongst the 9 patients. As revisions are typically associated with expensive hospital admissions for both the child and family, reducing the number of revisions needed is invaluable to those impacted.Continue reading